

RESEARCH ARTICLE

GAPDH mediates drug resistance and metabolism in *Plasmodium falciparum* malaria parasites

Andrew J. Jezewski^{1,2#a}, Ann M. Guggisberg^{1#b}, Dana M. Hodge^{1#d}, Naomi Ghebremichael¹, Gavin Nicholas John^{1#d}, Lisa K. McLellan^{1#c}, Audrey Ragan Odom John^{1,2#d*}

1 Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, United States of America, **2** Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America


#a Current address: Department of Pediatrics, University of Iowa, Iowa City, Iowa, United States of America

#b Current address: Pluton Biosciences, Inc., St. Louis, Missouri, United States of America

#c Current address: Department of Biology, Massachusetts Institutes of Technology, Cambridge, Massachusetts, United States of America

#d Current address: Department of Pediatrics, Children's Hospital of Philadelphia, and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

* johna3@chop.edu



OPEN ACCESS

Citation: Jezewski AJ, Guggisberg AM, Hodge DM, Ghebremichael N, John GN, McLellan LK, et al. (2022) GAPDH mediates drug resistance and metabolism in *Plasmodium falciparum* malaria parasites. PLoS Pathog 18(9): e1010803. <https://doi.org/10.1371/journal.ppat.1010803>

Editor: Sean T. Prigge, Johns Hopkins Bloomberg School of Public Health, UNITED STATES

Received: November 9, 2021

Accepted: August 9, 2022

Published: September 14, 2022

Copyright: © 2022 Jezewski et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Sequencing reads are available in the Sequence Read Archive (SRA) of the National Center for Biotechnology Information (NCBI), part of BioProject PRJNA222697. Individual SRA Accession numbers can be found in [S1 Table](#). All other relevant data are within the manuscript and its supporting information, including an Excel data file that includes all raw data used to generate graphs and figures.

Funding: A.J.J. was supported by NIH T32GM007067 and 2T32AI007511. A.M.G. was

Abstract

Efforts to control the global malaria health crisis are undermined by antimalarial resistance. Identifying mechanisms of resistance will uncover the underlying biology of the *Plasmodium falciparum* malaria parasites that allow evasion of our most promising therapeutics and may reveal new drug targets. We utilized fosmidomycin (FSM) as a chemical inhibitor of plastidial isoprenoid biosynthesis through the methylerythritol phosphate (MEP) pathway. We have thus identified an unusual metabolic regulation scheme in the malaria parasite through the essential glycolytic enzyme, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Two parallel genetic screens converged on independent but functionally analogous resistance alleles in GAPDH. Metabolic profiling of FSM-resistant *gapdh* mutant parasites indicates that neither of these mutations disrupt overall glycolytic output. While FSM-resistant GAPDH variant proteins are catalytically active, they have reduced assembly into the homotetrameric state favored by wild-type GAPDH. Disrupted oligomerization of FSM-resistant GAPDH variant proteins is accompanied by altered enzymatic cooperativity and reduced susceptibility to inhibition by free heme. Together, our data identifies a new genetic biomarker of FSM-resistance and reveals the central role of GAPDH in MEP pathway control and antimalarial sensitivity.

Author summary

Malaria is a life-threatening mosquito-borne infection that remains an enormous public health threat worldwide, with over 600,000 deaths reported in 2020 alone. The parasites that cause malaria invade and replicate within human red blood cells. This unique

supported by the Monstanto Excellence Fund Graduate Fellowship. L.K.M. was supported by the Mr. and Mrs. Spencer T. Olin Fellowship for Women. A.O.J. is supported by NIH/NIAID R01-AI103280, R21-AI123808, and R21-AI130584, and A OJ is an Investigator in the Pathogenesis of Infectious Diseases (PATH) of the Burroughs Wellcome Fund. The Genome Technology Access Center at the McDonnell Genome Institute at Washington University School of Medicine is partially supported by the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding websites: NIH <https://www.nih.gov> Burroughs Wellcome Fund <https://www.bwffund.org> Monsanto Fund: <https://medicine.wustl.edu/news/monsanto-funds-fellowships-graduate-students/> Olin Fellowship: <https://graduateschool.wustl.edu/olin-fellowship>.

Competing interests: The authors have declared that no competing interests exist.

environment provides the malaria parasite with almost unlimited supply of sugar in the form of glucose, which the parasite uses for energy and as building blocks to grow and divide. Parasites break down glucose, and must use these breakdown products to make new molecules, including a very important class of compounds called isoprenoids. Malaria parasites normally die when they are treated with a drug, called fosmidomycin, that inhibits this process. To understand how parasites regulate this critical function, in this study we identified parasites that were resistant to fosmidomycin. These fosmidomycin-resistant cells had mutations in an enzyme that is critical for sugar breakdown, called glyceraldehyde phosphate dehydrogenase (GAPDH). We find that parasites with mutant GAPDH enzymes still break down sugar normally, but are not inhibited by other changes in the cell that happen upon fosmidomycin treatment. These results reveal a new and important role for the enzyme GAPDH as a control-point for downstream metabolism in malaria parasites.

Introduction

Worldwide, malaria causes more than 600,000 fatalities each year, predominantly in young infants and pregnant women [1]. Successful clinical management of life-threatening blood-stage infections with *Plasmodium falciparum* relies on a rapid response to antimalarial chemotherapeutics [2,3]. Because of widespread antimalarial resistance to older agents, the newer artemisinin-based combination therapies (ACTs), which quickly reduce parasite loads, are first-line therapeutic agents [4]. Expanding resistance to ACTs, characterized by delayed parasite clearance during treatment, has created a pressing public health need to develop antimalarials with novel modes of action [5–8]. Identifying novel biological processes that may serve as useful drug targets is an important approach in the ongoing efforts toward malaria elimination [9,10]. A deep understanding of essential parasite biology, particularly those parasite processes that are distinct from the human host, will open new possibilities for therapies effective against drug-resistant *P. falciparum*.

P. falciparum possesses an unusual plastid organelle termed the apicoplast, which was originally acquired through an ancient endosymbiotic event of a plastid-bearing red alga [11,12]. While photosynthetic capacity has been lost over evolutionary time, this unique organelle has been retained by most modern Apicomplexans because it contributes essential metabolic products [13,14]. In particular, isoprenoid precursors generated by the apicoplast are essential for asexual development of *P. falciparum* [15,16]. Isoprenoids are a diverse set of biomolecules that contribute to organismal color (carotenoids) and odor (volatiles), and are also required for indispensable cellular functions, such as protein membrane anchoring and signaling (through prenylation) and electron transport (ubiquinone) [17,18]. Essential isoprenoids are derived from two five-carbon building blocks, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). While mammals, including humans, generate IPP/DMAPP through the mevalonate pathway, *Plasmodium* spp. produce these building blocks through an alternative metabolic route, the methylerythritol phosphate (MEP) pathway [19]. The cellular factors that control production of isoprenoid precursors and products in *Plasmodium* spp. are incompletely understood and likely to be highly divergent from those regulatory strategies employed in mammalian cells to control the mevalonate pathway. The essential and parasite-specific MEP pathway thus provides a compelling target for novel antimalarial treatments [20].

The MEP pathway of isoprenoid biosynthesis harnesses two glycolytic intermediates, glyceraldehyde 3-phosphate (G3P) and pyruvate (PYR) which are condensed into 1-deoxy-D-xylulose 5-phosphate (DOXP). This first committed step involves the conversion of DOXP into

2-C-methyl-D-erythritol 4-phosphate (MEP) by the enzyme DOXP reductoisomerase (DXR; E.C. 1.1.1.267). The phosphonate antibiotic fosmidomycin (FSM) is a highly specific, competitive inhibitor of DXR. We have previously employed FSM as a chemical tool to identify novel modes of metabolic regulation in *P. falciparum*. Parasite resistance to FSM is primarily mediated through loss-of-function mutation in one of two closely related small molecule phosphatases, HAD1 (E.C. 3.1.3.23; encoded by PF3D7_1033400) or HAD2 (PF3D7_1226300). HAD1 and HAD2 are members of the large haloacid dehalogenase protein superfamily of phosphotransferases [21,22]. Loss of either HAD phosphatase applies metabolic pressure on central carbon metabolism—in particular glycolysis—to divert metabolic precursors toward isoprenoid biosynthesis and achieve FSM resistance. In the case of *had2* mutant parasites, this metabolic dysregulation leads to a fitness cost in asexual replication of the parasite that can be compensated by secondary, hypomorphic alleles in the glycolytic enzyme phosphofructokinase (PFK) (E.C. 2.7.11; PF3D7_0915400) [22]. These “second site” mutations in PFK restore FSM sensitivity.

These previous studies highlight a central role for glycolytic regulation in maintaining MEP pathway balance and functionality. Traditionally, PFK serves as the rate-determining step in glycolysis where plants, mammals, and microbes have evolved several layers of regulation. It is therefore not surprising that mutations would arise in PFK to affect glycolytic balance in relation to the MEP pathway. However, not all metabolic states support PFK as the chokepoint in glycolysis. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) serves as a critical chokepoint for glycolytic flux under aerobic fermentation, when glucose consumption is high in the presence of oxygen but the absence of TCA cycle respiration [23,24]. This Warburg-like metabolic state is common in rapidly proliferating cells like tumors but also in *Plasmodium* parasites, as glucose nearly acts as the sole energy-producing carbon source with almost no aerobic respiration during the asexual blood-stage. In this state, GAPDH serves as a gate-keeper between upper (energy-consuming preparatory phase) and lower (energy-producing payoff phase) glycolysis. Beyond its glycolytic function GAPDH functions in multiple other cellular processes including apoptosis, transcription, vesicular trafficking, and heme detoxification [25–30]. Currently, the *Plasmodium* GAPDH has not been implicated as a determinant of drug resistance, overall pathogenicity, or a regulator of accessory cellular functions let alone controlling metabolic plasticity despite its primary role as a glycolytic enzyme.

In our continued search of novel modes of FSM resistance we continue to uncover novel biological processes important for parasite function. We present a combination genetic screening strategy that utilizes both enhanced FSM resistance selection and multi-round FSM resistance/suppression cycling. Together, these two independent screens converge on GAPDH (E.C. 1.2.1.12; PF3D7_1462800) as an important regulator of glycolytic balance and provide the possibility for a secondary accessory role for GAPDH as a heme chaperone that is unique from mammalian GAPDH. This unique mode of metabolic regulation in *Plasmodium* is likely to reveal novel drug targets and therapeutic strategies.

Results

Enhanced FSM resistance in malaria parasites selects for GAPDH variant

FSM is a highly specific inhibitor of the MEP pathway, which produces the essential isoprenoid precursors IPP and DMAPP. We have previously shown that *P. falciparum* malaria parasites with loss-of-function mutations in the haloacid dehalogenase, HAD1 (PF3D7_1033400), have elevated levels of MEP pathway metabolites, which confers FSM resistance [half maximal effective concentration (EC_{50}) of $4.63 \pm 0.46 \mu\text{M}$ (compared to $0.88 \pm 0.05 \mu\text{M}$ for wild-type (WT) parasites)] [21]. To investigate the presence of other metabolic regulators that may be acting in concert with or independently of HAD1, we increased FSM selection pressure in the already




Fig 1. Two FSM-resistance screening strategies both select for *gapdh* alleles. (A) Schematic of the FSM resistance enhancer screen and variant alleles identified from whole genome sequencing of FSM-resistant (FSM^R) *P. falciparum*. (B) The corresponding FSM EC₅₀ resistance phenotyping data for the enhancer screen. (C) Schematic of the FSM resistance cycling screen and variant alleles identified from whole genome sequencing that yielded FSM^R *P. falciparum* parasites from re-sensitized FSM^R parasite lines. (D) The corresponding FSM EC₅₀ resistance phenotyping data for the cycling screen. FSM = fosmidomycin, *had* = haloacid dehalogenase 1/2, *gapdh* = glyceraldehyde 3-phosphate dehydrogenase, *pfk9* = phosphofructokinase 9.

<https://doi.org/10.1371/journal.ppat.1010803.g001>

resistant *had1* parasite strain (Fig 1). This “enhancer screen” yielded a mixed parasite population that was capable of growth in elevated FSM (10 µM). Two independent clones were derived from this population and likewise exhibited heightened FSM resistance, quantified as >35-fold resistant over WT and >6-fold over their immediate *had1* parent, respectively [33.0 ± 1.02 µM and 31.5 ± 2.76 µM, $p < 0.0001$ compared to WT and *had1* parent with one-way ANOVA and follow-up Bonferroni corrected t-tests (S1 Table, S1 Fig)]. Sanger sequencing verified that this enhanced resistance was not the result of previously described variants in an alternative FSM-resistance locus encoding HAD2 (PF3D7_1226300). Whole genome sequencing on both enhanced FSM resistant clones revealed a novel T626C allele in the gene encoding the canonical glycolytic enzyme, glyceraldehyde 3-phosphate dehydrogenase (GAPDH; PF3D7_1462800). These two clonal FSM resistant strains are hereafter referred to as *had1 gapdh-1a* and *had1 gapdh-1b* (S1 Table). The *de novo gapdh* allele exists in the second exon of GAPDH and encodes the missense variant GAPDH^{I209T}.

Cycling FSM selection pressure gives rise to separate variant in GAPDH

In parallel to the “enhancer screen” described above, we also employed a second and independent genetic screening strategy (Fig 1). As previously reported, loss of a homologous haloacid

dehalogenase, HAD2 (PF3D7_1226300), also results in FSM resistance ($EC_{50} = 4.80 \pm 1.20 \mu\text{M}$), separately from *had1*. Because loss of HAD2 dysregulates central carbon metabolism in *P. falciparum*, *had2* parasites experience a pronounced fitness cost, such that when FSM selection pressure is removed, the *had2* strain acquires new suppressor mutations in the glycolytic enzyme, phosphofructokinase-9 (PFK9) [22]. This *had2 pfk9* strain is again FSM sensitive ($EC_{50} = 0.42 \pm 0.04 \mu\text{M}$) and we have previously determined that PFK9 mutations relieve the dramatic metabolic dysregulation caused by loss of HAD2 [22]. To understand the limits of this metabolic plasticity, we iteratively applied FSM selection pressure to the *had2 pfk9* FSM sensitive strain. From three independent selections, we generated FSM resistance and isolated two clones from each selection. All clones exhibited 3–4-fold resistance compared to the *had2 pfk9* strain (S1 Table, S1 Fig). Sanger resequencing confirmed that this resistance was not the result of newly acquired variants in HAD1. To identify the genetic changes responsible for FSM resistance, we performed whole genome sequencing on clones from three independent selections (two clones per selection). Our sequencing converges on a single common locus with a T713C mutation in GAPDH, giving rise to strains *had2 pfk9 gapdh-1a*, *-1b*, *-2a*, *-2b*, *-3a*, and *-3b*, respectively (S1 Table). This new resistant GAPDH allele is also present in the second exon of the gene and encodes the novel missense variant GAPDH^{V238A}.

Two independent selection approaches converge on variants at the dimer interface of GAPDH

Our previous resistance screens demonstrated that changes in glycolytic metabolic regulation can be used by malaria parasites to confer altered FSM sensitivity. For this reason, we considered the convergent SNPs in the locus encoding the glycolytic enzyme GAPDH as compelling candidates to mediate FSM resistance. Complete loss of GAPDH function would be unlikely, given the essential role for glycolytic function and the need for GAPDH to supply pyruvate for the MEP pathway. To understand how these GAPDH alleles might impact protein function, we modeled the position of the encoded variants on the published tertiary and quaternary structure of *Pf*GAPDH. Both the GAPDH^{I209T} and GAPDH^{V238A} variants are distant from the substrate-binding pocket and are not predicted to directly impact catalysis (Fig 2). Surprisingly, we found that both I209 and V238 are immediately physically adjacent in three-dimensional space. Both residues are present at the base of a relatively disordered S-loop, which is normally stabilized by the oligomerization of the GAPDH homo-tetramer (PDB: 2B4R) [31]. Interestingly, we find that not only are I209 and V238 adjacent within a single monomer, they are predicted to directly interact at the hydrophobic interface of two of the homodimer subunits (Fig 2). Classically, hydrophobic surfaces drive protein-protein interactions. Both FSM-resistant variants alter hydrophobic residues (isoleucine to threonine and valine to alanine, respectively). Therefore, we hypothesized that GAPDH oligomerization was disrupted in our variants and that this was the structural mechanism of FSM resistance in our strains.

GAPDH tetramer formation is disrupted in FSM-resistant GAPDH variant enzymes

To test this model, we sought to quantify oligomer formation in wild-type GAPDH and its FSM-resistant variants. We performed analytical high-resolution size exclusion chromatography (SEC) (Figs 3 and S2), which accurately separates GAPDH monomers and multimers. SEC analysis of GAPDH^{WT} reveals a single dominant peak that corresponds to the tetrameric state (molecular weight of 150 kD, compared to the GAPDH monomer of 37kD). In contrast, both the GAPDH^{I209T} and GAPDH^{V238A} variants exhibit three peaks, which correspond to the




Fig 2. GAPDH mutations from separate FSM resistance screens converge at the homo-dimer interface. Two subunits forming one dimer of the GAPDH tetramer are displayed as ribbon representations in purple and orange with corresponding transparent surfaces. Side chains of the mutation locations are displayed as sphere representations and labeled with white text sitting at the dimer interface and at the base of the S-loop. NAD cofactors are shown as stick figures bound to their respective active sites in yellow (PDB_ID: 2B4R).

<https://doi.org/10.1371/journal.ppat.1010803.g002>

tetrameric (150kD), dimeric (83kD), and monomeric (~40kD) states. Loss of the dominant tetramer peak in both FSM-resistant variant proteins confirms that protein-protein interactions in these GAPDH variants are markedly disturbed.

Enzymatic characterization of FSM-resistant GAPDH variant enzymes

Plasmodium spp. express a phosphorylating GAPDH (E.C. 1.2.1.12) that converts glyceraldehyde 3-phosphate into 1,3-bisphosphoglycerate utilizing inorganic phosphate in an NAD +-dependent manner. However, tetramerization of GAPDH is not required for catalysis. Because our FSM-resistant alleles alter residues at the dimer interface that are distant from the active site, we predicted that these GAPDH variants might impact multimerization but would not disrupt the glycolytic function of GAPDH. This model also agrees with our metabolite profiling data, which supports no significant differences in levels of the glycolytic products PYR and LAC. To test this hypothesis, we successfully expressed and purified recombinant wild-type and both FSM-resistant variant proteins (S3 Fig). Robust glyceraldehyde-3-phosphate dehydrogenase activity was observed for all three protein variants (WT, GAPDH^{V238A}, and GAPDH^{I209T}), with a decrease in enzyme turnover only detected for GAPDH^{V238A} ($k_{cat} = 7.0 \pm 1.0 \text{ s}^{-1}$) but not GAPDH^{I209T} ($k_{cat} = 55.3 \pm 6.1 \text{ s}^{-1}$) compared to GAPDH^{WT} ($k_{cat} = 49.1 \pm 7.6 \text{ s}^{-1}$), $p < 0.001$ GAPDH^{V238A} vs. GAPDH^{WT} (Fig 4). While modestly reduced enzyme turnover was observed for GAPDH^{V238A} *in vitro*, this may reflect the difference between distinct protein preps that may not translate to biologically meaningful differences *in vivo*, which agrees with our metabolic profiling data. FSM-resistant and wild-type enzymes shared Michaelis-Menten constants for all three substrates NAD⁺, GAP, and P_i (S4 Fig).

In contrast, we find marked differences in inorganic phosphate (Pi) cooperativity between FSM-resistant GAPDH variant enzymes compared to the wild-type enzyme. Cooperativity is a




Fig 3. Size exclusion chromatography depicts altered oligomer formation of FSM^R GAPDH variant proteins. Size exclusion chromatography traces of recombinant proteins (1mg/mL) with oligomeric states illustrated below. Ve = void volume of the column. Traces of mutant proteins are inverted below the x-axis.

<https://doi.org/10.1371/journal.ppat.1010803.g003>

fundamental feature of many multi-subunit proteins, and GAPDH has long been studied as a model of enzymatic cooperativity [32]. The binding of small molecule ligands to individual protein subunits leads to conformational changes that induce an increased or decreased ability of substrate to bind to the remaining substrate-binding sites. In the case of GAPDH, P_i exhibits positive cooperativity. This cooperativity can be quantified by the Hill constant (H), which approximates the number of substrate binding sites. Both variant enzymes display lower positive cooperativity, as indicated by substantially lower Hill constants (GAPDH^{I209T}, $H = 2.2 \pm 0.2$; GAPDH^{V238A}, $H = 2.9 \pm 0.2$, compared to GAPDH^{WT}, $H = 5.1 \pm 0.2$). These findings in conjunction with our size exclusion data suggest a model in which the multimeric assembly is likely disrupted in our fosmidomycin-resistant variant GAPDH enzymes (Fig 4).




Fig 4. FSM^R GAPDH variants support robust catalytic efficiency but exhibit altered cooperativity. (A) Catalytic efficiency of recombinant GAPDH protein variants. A statistically significant decrease in catalytic efficiency is measured for the GAPDH^{V238A} variant compared to WT. (B) FSM^R GAPDH variant proteins display lower cooperativity for phosphate substrate. Hill constants were calculated using GraphPad Prism, using non-linear regression for cooperativity. Statistical comparisons, one-way ANOVA followed by a Tukey post-hoc adjustment for multiple comparisons, ** = $p < 0.01$, *** = $p < 0.001$.

<https://doi.org/10.1371/journal.ppat.1010803.g004>

Fosmidomycin-resistant GAPDH variants are also refractory to heme inhibition

GAPDH has been shown to participate in many other cellular processes including apoptosis, transcription, vesicular trafficking, and heme detoxification [25–30]. The latter is particularly important with regards to parasite biology [33,34]. The parasite's consumption of hemoglobin results in large amounts of toxic heme that must be sequestered as hemozoin crystals in the parasite's food vacuole. Coincidentally, FSM treatment results in disruption in food vacuolar integrity (S5 Fig) [35]. This creates a unique crossroads between GAPDH's ability to serve as a regulator during metabolic stress, heme toxicity, and drug resistance. While many non-glycolytic roles of GAPDH involve oligomer formation, not all of these non-glycolytic roles are independent from the glycolytic function of GAPDH, especially as a heme chaperone. Therefore, we decided to evaluate whether heme binding was disrupted in our FSM-resistant GAPDH variants. Because heme inhibits the catalytic function of GAPDH, we tested the enzymatic function of our recombinant variant protein compared to wild-type, in the presence or absence of increasing concentrations of free heme. We find that heme inhibits the catalytic function of the wild-type GAPDH protein ($EC_{50} = 2.98\mu\text{M}$) in a dose-dependent manner. In contrast, FSM-resistant GAPDH variants are highly resistant to heme inhibition ($EC_{50} > 10\mu\text{M}$, Fig 5A). This observation supports the hypothesis that FSM toxicity partly driven by heme toxicity is uncoupled from glycolytic disruption in these GAPDH mutant strains. We find that GAPDH variants that are refractory from heme inhibition do not lose the ability to bind heme. Instead, these variant proteins exhibit an altered interaction with heme, visualized by a shift in heme-protein absorption maxima (GAPDH^{WT}, $Abs_{max} = 416\text{nm}$; GAPDH^{I209T}, $Abs_{max} = 406\text{nm}$) (Fig 5B), reduction in binding affinity (GAPDH^{WT}, $K_d = 0.74$; GAPDH^{I209T}, $K_d = 1.84\mu\text{M}$), and a reduction in cooperativity (GAPDH^{WT}, $H = 3.5$, GAPDH^{I209T}, $H = 1.2$) (Fig 5C). This reduction in cooperativity agrees with the reduced phosphate cooperativity observed enzymatically.

FSM-resistant *gapdh* strains maintain glycolytic output under FSM treatment

To directly test our hypothesis that these GAPDH mutants uncouple the metabolic impacts of FSM, we performed metabolite profiling of MEP pathway and glycolytic intermediates to




Fig 5. FSM^R GAPDH variants are resistant to inhibition by heme and exhibit altered heme binding. (A) Dose-responsive inhibition of GAPDH enzymatic activity by heme. Percent maximum activity determined from Abs340/minute normalized to untreated control. (B) Heme:recombinant GAPDH binding absorption spectrum. Absorbance is background subtracted from heme without protein at each concentration of heme. GAPDH is held in excess at 1mg/mL. Spectra were generated and absorption maxima calculated using Spectragryph and replotted in GraphPad Prism. (C) Heme:recombinant GAPDH binding affinity curve derived from changes in the absorption maxima with each addition of heme as plotted in B. Inhibition (GAPDHWT K_d = 0.74, GAPDH^{I209T} K_d = 1.84μM) and Hill constants were calculated using a cooperative binding fit using non-linear regression functions in GraphPad Prism.

<https://doi.org/10.1371/journal.ppat.1010803.g005>

identify the shared metabolic differences of these *gapdh* strains (*had1/gapdh-a*, *had2/pfk9/gapdh-2a*, *-3a*) compared to their direct parents (*had1*, *had2/pfk9*), with and without FSM treatment (S6A Fig). A type III two-way ANOVA using a Bonferroni correction for multiple comparisons reveals two metabolites with significant differences: 2-C-methyl-D-erythritol-2,4,-cyclopyrophosphate (MEcPP) with respect to inhibitor treatment ($p = 0.029$), and glycerol 3-phosphate (Gly3P) with respect to genotype ($p < 0.001$) (S6B Fig). An untargeted metabolic profiling approach may have detected additional metabolic differences; however, as expected, levels of the MEP pathway product MEcPP are significantly reduced for all strains under FSM treatment, which competitively inhibits the MEP pathway upstream of MEcPP production. Although *gapdh* variants have a modest reduction in glycolytic products Lactate (LAC) and Pyruvate (PYR), no significant changes in LAC or PYR levels were observed compared to either immediate parental strain. These data indicate that our FSM-resistance *gapdh* variants nonetheless maintain normal glycolytic output.

To determine the role of GAPDH in the context of FSM treatment, we assessed whether GAPDH operates at an inflection point for glycolysis in asexual *P. falciparum* in the presence or absence of FSM treatment. To provide a quantitative measure of these changes, we define “metabolic balance,” as the ratio of the abundance of metabolites upstream of GAPDH [glucose 6-phosphate (G6P), glucose/fructose 1/6-phosphate (G1P/F6P), G3P, and Gly3P] to the abundance of metabolites downstream [phosphoenolpyruvate (PEP), PYR, and LAC] (Fig 6A). We then compared this metabolic balance before and after FSM treatment. We find that FSM dramatically alters metabolic balance in malaria parasites, such that metabolites upstream of GAPDH are elevated relative to metabolites downstream (Fig 6B). In contrast, FSM-resistant *gapdh* mutant strains preserve substrate availability to the lower half of glycolysis (quantified by metabolic balance) in the presence of FSM ($p < 0.05$, unpaired t-test). These data suggest that FSM treatment induces a metabolic disruption in central carbon metabolism that is most pronounced at the level of GAPDH. FSM-resistant GAPDH variants confer FSM resistance through relief of this imbalance (Fig 6C).

GAPDH mutants confer FSM resistance through substrate availability

Our previously reported FSM resistance screens have identified mutants that overcome competitive FSM inhibition by controlling substrate availability to the MEP pathway. We sought to evaluate whether mutations in GAPDH are mechanistically distinct and develop FSM




Fig 6. Fosmidomycin-induced metabolic imbalance is relieved by mutations in GAPDH. (A) Schematic showing metabolites upstream and downstream of GAPDH function. Abundance ratios (FSM + / FSM -) are displayed for parent (par) and mutant (mut) strains. Data from both parents and both mutant strains were grouped to identify metabolic differences driven by GAPDH mutant status. Z-scores represent differences within genotypes across metabolites. (B) Metabolic balance is displayed as the fold change in total abundance of metabolites upstream over the total abundance of metabolites downstream in the presence of FSM, therefore an increase in upstream metabolites relative to downstream metabolites indicates a reduced GAPDH function. FSM induces a significantly different metabolic imbalance in parent (par) strains compared to *gapdh* mutant (mut) strains, * = $p < 0.05$ (C) Schematic illustrating the metabolic imbalance that is resolved by GAPDH mutants under FSM stress.

<https://doi.org/10.1371/journal.ppat.1010803.g006>

resistance by relieving the toxic effects of reduced isoprenoid metabolism. To assess this possibility, we determined the sensitivity of each *gapdh* mutant strain, compared to their direct parent strain, to the CTP-competitive IspD inhibitor, MMV008138 [36]. Neither *gapdh* mutant strain exhibits increased resistance to MMV008138 (S7 Fig). This supports a mechanism of FSM resistance where GAPDH mutants promote bulk flow of glycolytic substrates to the MEP pathway. In addition, we sought to rescue FSM sensitivity using exogenously supplied glycolytic intermediates glyceraldehyde 3-phosphate and phosphoenolpyruvate, which are metabolically upstream of MEP metabolism. Neither intermediate alleviates FSM inhibition, likely due to the lack of uptake.

Discussion

Two independent FSM drug screening strategies in separate *P. falciparum* strains achieved FSM resistance through a common target, GAPDH. Together, we identified a genetic, molecular, structural, and metabolic mechanism of FSM resistance, which may otherwise not have been identified without these converging screening strategies. Our study reveals an important overall mechanism of metabolic plasticity in *Plasmodium falciparum*, which is the leading cause of death due to malaria.

Metabolic plasticity can be described by an organism's ability to alter metabolism in response to internal and external signals to provide optimal output of metabolic products. Pushing the limits of an organism's natural metabolic plasticity presents a strategy for identifying metabolic regulators. By targeting an essential downstream metabolic process (isoprenoid production) with a specific chemical inhibitor (FSM), we selected for *Plasmodium falciparum* parasites that

have evolved through genetic alterations in metabolic machinery. Thus, FSM resistance continues to serve as an important chemical tool for uncovering essential metabolic regulatory mechanisms in malaria parasites. Resistance to a given inhibitor may be achieved through multiple possible mechanisms, including inhibitor transport (import/efflux), molecular modification, and mutations in the inhibitor target. Each of these possible alternative modes of resistance would provide minimal information about metabolic mechanisms of resistance. Despite these alternative modes of resistance and by pushing the boundaries of FSM's effects on parasite metabolism, we have identified a new metabolic focal point for achieving FSM resistance.

Given the possible alternative modes of FSM resistance and the continued preference for metabolic alterations in achieving resistance, we have learned an important feature of this small molecule. Our continued selection of metabolic regulatory mechanisms suggests that the fitness cost of metabolic alterations to overcome resistance is far less than the fitness cost of transport or drug target mutations. This observation emphasizes two important points. The first is that the function of the FSM target, DXR, is highly essential and that mutations which render FSM ineffective are not favorable for the essential function of DXR in isoprenoid precursor biosynthesis [37]. The second is that FSM transport occurs through a route that is likely essential for parasite survival. This observation is counter to what is described in bacteria, where the FSM transporter GlpT is not essential and is readily mutated to achieve FSM resistance [38–40]. This stresses the importance of future studies to identify the FSM transporter, likely a novel druggable target.

As a parasite, *Plasmodium falciparum* has a characteristically reduced metabolic robustness given the stable supply of glucose and other nutrients in the blood stream [41]. Many of the canonical metabolic modes of regulation that have been described in model organisms do not translate to the parasites' metabolism, including the lack of an annotated phosphofructose biphosphatase (FBP) to carry out the reverse step of glycolysis at the level of PFK. Given the reduced metabolic functions within the parasite, much of what remains is a central carbon metabolic skeleton where the metabolites that cannot be scavenged from the host are mostly derived from the glucose uptake of the parasite. Most of this glucose (>90%) flows through glycolysis for ATP production, but a small portion is partitioned toward other essential metabolic processes [42]. Our use of FSM as a tool for probing metabolic plasticity has helped us identify the mechanisms that regulate this metabolic partitioning. The current study uncovers a novel mechanism of metabolic regulation through GAPDH.

GAPDH serves an important metabolic role in catalyzing the sixth step of the classical Embden-Meyerhof-Parnas (EMP) pathway of glycolysis, the oxidation of G3P to 1,3-bisphosphoglycerate (1,3BPG), which also yields the reduced product NADH. In glycolysis, GAPDH both follows G3P and proceeds PYR production, which are the two precursor substrates of the MEP pathway. This provides a unique opportunity for GAPDH to maintain balanced substrate flow into the MEP pathway. Beyond its glycolytic metabolic function, GAPDH is involved in multiple other biological processes with roles as diverse as transcriptional regulation, vesicle trafficking, and heme trafficking. Unique to *Plasmodium* spp. is a link between GAPDH's heme chaperone role and its glycolytic function. The glycolytic function of *Pf*GAPDH is inhibited by heme binding while the mammalian GAPDH is not [43,44]. This closely ties heme toxicity to metabolic regulation. This is in addition to the regulation of GAPDH function through the formation of tetrameric or dimeric states and the dissociation into its monomeric form. While the ability to perform "alternative" functions may require oligomerization, the glycolytic function does not require oligomer formation.

The most compelling aspect of our discovering novel metabolic control through GAPDH is that two independent screens with the same phenotype of FSM resistance converged on the same genetic locus. Importantly, these mutations were not genetically identical but functionally the same. Our separate non-synonymous mutations generated protein alterations at the same

part of the protein responsible for driving multimerization. Disruption of this multimerization changed the ability of heme to inhibit the glycolytic function of GAPDH. Unlike *HsGAPDH*, *PfGAPDH* is normally inhibited by heme, as has been previously described [43]. Heme plays a particularly important biological role in parasite biology [34,45,46]. As the parasite requires hemoglobin digestion for scavenging amino acids it faces a unique problem of detoxifying the heme iron important for the oxygen carrying function of hemoglobin. The parasite mainly achieves this through the polymerization of heme into the characteristic hemozoin crystals found in the parasite food vacuole [45,47]. However, it is still not fully understood how heme is scavenged, transported, and detoxified within the parasite's cytosol. Recently, GAPDH has been described in other organisms to play a pivotal role in trafficking heme and inserting it into heme requiring apo-proteins, such as iNOS in humans [26,48]. And while a similar function may exist for *Plasmodium* GAPDH, others have hypothesized that GAPDH may serve as a finely tuned heme sensor where the parasite responds to elevated heme by shutting down glycolysis and increasing metabolic flow into the pentose phosphate pathway to generate reducing equivalents [49]. This proposed paradigm works well to address oxidative stresses induced by heme only if the cause of rising heme isn't in conflict with uninhibited GAPDH function. In the case of FSM treatment, where food vacuole integrity is disrupted and therefore presumably causes a concomitant increase in cytosolic heme, the inhibition of GAPDH would further starve the MEP pathway of its precursor metabolites and exacerbate FSM toxicity [35]. Our model proposes that under FSM selection pressure parasites respond to reduce this toxicity by eliminating the heme responsiveness of GAPDH in its metabolic function (Fig 7). Further studies are required to accurately measure cytosolic heme concentrations in relation to the heme responsiveness of GAPDH, although previous measures of cytosolic heme indicate concentrations ~2-fold less than what we report is required for heme inhibition [50]. This allows increased bulk flow of MEP pathway substrates to overcome the competitive inhibition of FSM.

As a highly conserved enzyme across the entire kingdom of life, GAPDH has been adapted to perform many other important biological functions. We have shown that *Plasmodium falciparum* is no exception. Roles for GAPDH include regulation of cell death, transcription, oxidative stress, nitrosative stress, vesicle trafficking, and now drug resistance [28,51,52]. In many of these other possible roles for GAPDH multimerization is likely a factor in performing its function. We now have multimerization mutants in *Plasmodium falciparum* to begin to study these alternative functions. The one-gene one-enzyme hypothesis certainly does not apply to one-function. We aim to understand these possible alternative non-metabolic functions and how they may still play a part in regulating metabolism indirectly.

Methods

Maintaining *P. falciparum* cultures

Parasite strains are derived from 3D7 (MRA-102) as deposited by Daniel J. Carucci at the Malaria Research and Reference Resource Center as part of BEI Resources and established by the National Institutes of Allergy and Infectious Diseases. Parasite cultures were maintained in a suspension of human erythrocytes at 2% hematocrit in complete media (RPMI-1640, Millipore-Sigma, supplemented with 27mM sodium bicarbonate, 11mM glucose, 5mM HEPES, 1mM sodium pyruvate, 0.37mM hypoxanthine, 0.01 mM thymidine, 10 $\mu\text{g ml}^{-1}$ gentamycin, and 0.5% Albumax, Life Technologies) under 5% O₂/5% CO₂/90% N₂ atmosphere at 37°C. Human erythrocytes were obtained from banked blood kindly provided by the Saint Louis Children's Hospital. Donated blood is filtered to remove leukocytes. All blood is triple washed using incomplete media (RPMI-1640, Millipore-Sigma) and stored at 50% hematocrit at 4°C. Erythrocytes are used up to 1 month past the clinical expiration date.




Fig 7. Model of GAPDH-dependent FSM sensitivity. (A) Untreated intraerythrocytic wild-type *P. falciparum*. Digestive food vacuole (FV) is intact, containing heme, and tetrameric GAPDH supports robust glycolytic output. (B) FSM-treated wild-type infected red cell. Loss of FV integrity releases heme, which inhibits tetrameric GAPDH and reduces glycolytic output. (C) Untreated GAPDH mutant infected red cell. Reduced oligomerization of mutant GAPDH maintains normal glycolytic output. (D) FSM-treated GAPDH mutant infected red cell. Loss of FV integrity releases heme. Because dimeric GAPDH is less sensitive to heme inhibition, glycolytic output is preserved. Red shape = red cell host, purple shape = *P. falciparum* parasite, brown shape = food vacuole. FSM = fosmidomycin.

<https://doi.org/10.1371/journal.ppat.1010803.g007>

Generating enhanced FSM resistant *P. falciparum*

Strain E1 was created as previously published and described [21]. As part of a larger enhanced resistance screening strategy strain E1 was first cloned by limiting dilution. The newly obtained clone was deemed strain E1-C12. From this clone independent selections were considered as separated wells. Parasites were continually cultured as described with the addition of 10 μ M FSM. Cultures that were positive for parasite growth were isolated and verified for FSM resistance as compared to strain E1-C12. Enhanced FSM-resistant strain 59 was cloned by limiting dilution. Two clones 59a and 59b were isolated, confirmed for FSM resistance, and submitted for whole genome sequencing.

Generating FSM resistance strains in FSM resistance suppressed *P. falciparum*

Strains E2 and E2-S1 were created as previously published and described [21,22]. Strain E2-S1 was first cloned by limiting dilution. The newly obtained clone was deemed strain E5. From this clone independent selections were performed in separated wells. Parasites were continually cultured as described with the addition of 0.5 μ M FSM. Cultures that were positive for parasite growth were isolated and verified for FSM resistance as compared to strain E5. Four independent FSM resistant isolates were selected and named E5-1, E5-2, E5-3, and E5-4. Each isolate was cloned by limiting dilution and two subclones were isolated for each, confirmed for FSM resistance, and submitted for whole genome sequencing.

Determination of half maximal FSM growth inhibition

Parasite cultures were diluted to 1% parasitemia and delivered to a 96-well plate along with an uninfected erythrocyte control. Serial dilutions of FSM were delivered along with a solvent control and cultures were incubated under normal culture conditions for three days. DNA was quantified using Picogreen (Life Technologies), as previously described [53]. Half-maximal effective concentration (EC_{50}) from nonlinear regression of normalized background-subtracted measurements of at least three biological replicates (GraphPad Prism).

Whole genome sequencing and variant discovery

Isolated DNA was submitted to the Washington University Genome Technology Access Center for library preparation, sequencing, read alignment and variant analyses. One microgram of genomic DNA was sheared, end repaired, and adapter ligated. Sequencing was performed on an Illumina HiSeq 2500 in Rapid Run mode to generate 101-bp paired-end reads. Demultiplexed reads were aligned to the *Plasmodium falciparum* 3D7 reference genome (PlasmoDB v7.2) using the short-read aligner Novoalign. Variants were called using samtools with a quality score greater than 37 and a minimum read depth of 5. Variants were annotated using snpEff. Variants present in the wild-type strain were removed from further analysis. Sequencing reads are available in the Sequence Read Archive (SRA) of the National Center for Biotechnology Information (NCBI), part of BioProject PRJNA222697. Individual SRA Accession numbers can be found in [S1 Table](#).

Sanger sequence verification of *PfGAPDH*

The regions with the gene that contained mutations were amplified from genomic DNA isolated from each parasite strain using the following primers: 5'-ATGGCAGTAA-CAAACTTGG-3' and 5'-TTAGTTGTTAGTAATGTGTACGG-3'. Purified PCR products were sequenced by the Protein and Nucleic Acid Laboratory at Washington University using BigDye Terminator v3.1 Cycle Sequencing reagents (Life Technologies) using primers: 5'-CCACCAATATGATACCAAAC-3', 5'-TCAGTGTATCCTAAGATTCC-3'. Sanger sequencing chromatograms were aligned to *gapdh* (PF3D7_1462800) using the SeqManPro software (DNAStar).

Recombinant expression, purification, and size exclusion chromatography of *PfGAPDH*

An *E. coli* codon-optimized *PfGAPDH* was produced (Genewiz) with N-term and C-term modifications for improved solubility as previously described [31]. Mutations for our corresponding mutant proteins were introduced using site-directed mutagenesis. Each sequence was then inserted via ligation-independent cloning into the isopropyl β -D-

1-thiogalactopyranoside (IPTG) inducible BG1861 expression vector. This creates an N-terminal 6x-His tag fusion protein used for nickel purification. Expression plasmids were transformed into One Shot BL21(DE3) *E. coli* cells (Thermo Scientific). Overnight starter cultures were diluted 1:1000 and grown to an optical density (O.D.) of ~0.6 where 1mM IPTG was added for 2 hours at 37°C. Cells were spun and stored at -80°C.

Expressed proteins were purified from cells using a sonication lysis buffer containing 1 mg/ml lysozyme, 20mM imidazole, 1mM dithiothreitol, 1mM MgCl₂, 10mM Tris HCl (pH7.5), 30 U benzonase (EMD Millipore), 1mM phenylmethylsulfonyl fluoride (PMSF), and EDTA-free protease inhibitor tablets. Lysates were clarified using centrifugation and proteins were purified via nickel agarose beads (Gold Biotechnology), eluted with 300mM imidazole, 20mM Tris-HCl (pH 7.5) and 150mM NaCl. Eluted proteins were further purified via size exclusion chromatography using a HiLoad 16/60 Superdex 200 gel filtration column (GE Healthsciences) using an AKTAExplorer 100 FPLC (GE Healthsciences). Fast protein liquid chromatography (FPLC) buffer contained 100mM Tris-HCl (pH 7.5), 1mM MgCl₂, 1mM DTT, and 10% w/v glycerol. Fractions containing purified protein were pooled, concentrated to ~2mg/ml as determined via Pierce BCA Protein Assay Kit (ThermoFisher), and stored by adding 50% glycerol for storage at -20°C. Analytical size exclusion chromatography was performed by loading 1mg of purified protein in 1mL of FPLC buffer. The same amount of protein was loaded for each protein and all proteins were prepped the same day and dialyzed in the same FPLC buffer the night before at 4°C.

Determination of *PfGAPDH* enzyme activity

Enzyme activity was determined spectrophotometrically at 340nm. The reaction was measured in buffer containing 10mM Tris-HCl pH 7.5, 200mM sodium chloride, 1mM magnesium chloride, 1mM DTT, 0.1 mg/mL bovine serum albumin (BSA), 25mM sodium phosphate (NaP_i), and 5mM NAD⁺. Recombinantly expressed proteins were added and allowed to incubate at 37°C for 10 minutes before starting the reaction with D-glyceraldehyde 3-phosphate (G3P). Assays were performed in a 96-well plate format and read by a microplate spectrophotometer (BMG Labtech). Conversion of NAD⁺ to NADH was determined using the extinction coefficient of 6,220 M⁻¹cm⁻¹. For pH dependence studies, the specific activity was determined in triplicate from reactions performed in a series of buffers (sodium phosphate, Tris, and CAPS) in escalating pHs from 5.8 to 10.5.

Michaelis-Menten kinetics

100μM NAD⁺, 64μM G3P, and 500μM P_i were each serially diluted according to the reaction mix described above. The activity assays were performed as described above. Nonlinear regression of the slopes of the different substrate concentrations yielded a Michaelis-Menten curve with corresponding K_m and V_{max} values for substrates G3P and NAD⁺. Allosteric sigmoidal plots were fitted for determining V_{max}, K_{half}, and Hill constants for P_i. (GraphPad Prism).

Heme inhibition of *PfGAPDH*

For inhibition studies a fresh stock of hemin (2.5mM) was prepared by dissolving hemin in 100mM NaOH with 5% DMSO. The stock hemin solution was diluted further to 1mM in 100mM NaOH with 5% DMSO. Hemin was diluted 1:5 in GAPDH reaction buffer as described above while maintaining 1mM NaOH across the dilution series. Purified recombinant GAPDH was confirmed to be resilient across moderate pH changes (S9 Fig). Serial dilutions of hemin were added to recombinant enzyme and allowed to incubate for 10 minutes at room temperature before being added to the standard GAPDH assay reactions described above.

For binding studies 1mg/mL of GAPDH recombinant protein was held constant while heme was titrated according to the reported dilution series. Heme absorbance spectra bound to GAPDH at each dilution was subtracted from unbound heme at the same dilution. Apparent binding constants were determined from the change in background subtracted absorbance across the dilution series.

Sample collection for LC/MS metabolite quantitation

Plasmodium falciparum strains were split into independent cultures at least two weeks before sample collection. Cultures were grown to ~10% parasitemia in 30mL volumes with 4% hematocrit. Cultures were then synchronized with 5% sorbitol treatment in successive rounds until >75% of parasites were in ring-stage growth. Ring-stage parasites were treated \pm FSM (5 μ M) (Life Technologies) for 12 hours. Collected cultures were placed on ice for metabolic quenching prior to parasite pellets collected via erythrocyte lysis induced with 0.1% saponin and centrifugation. Pellets were washed with PBS and flash frozen with LN₂ for storage at -80°C.

LC/MS sample extraction and analysis

MEP, TCA, glycolysis and PP pathway intermediates were extracted via the addition of glass beads (212–300 μ) and 600 μ L chilled H₂O: chloroform: methanol (3:5:12 v/v) spiked with PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid) as internal standard. The cells were disrupted with the TissueLyser II instrument (Qiagen) using a microcentrifuge tubes adaptor set pre-chilled for 2 min at 20 Hz. The samples were then centrifuged at 16,000 g at 4°C, the supernatants collected, and pellet extraction repeated once more. The supernatants were pooled and 300 μ L chloroform and 450 μ L of chilled water were added to the supernatants. The tubes were vortexed and centrifuged. The upper layer was transferred to a new tube and dried using a speed-vac. The pellets were re-dissolved in 100 μ L of 50% acetonitrile.

For LC separation of the MEP intermediates, a Luna-NH₂ column (3 μ m, 150 x 2 mm, Phenomenex) was used flowing at 0.4 mL/min. The gradient of the mobile phases A (20 mM ammonium acetate, pH 9.8, 5% ACN) and B (100% acetonitrile) was as follows: 60% B for 1 min, to 6% B in 3 min, hold at 6% B for 5 min, then back to 60% B in 0.5 min. For LC separation of the TCA/Glycolysis/PPP intermediates, an InfinityLab Poroshell 120 HILIC (2.7 μ m, 150 x 2.1 mm, Agilent) was used flowing at 0.5 mL/min. The gradient of the mobile phases A (20 mM ammonium acetate, pH 9.8, 5% ACN) and B (100% acetonitrile) was as follows: 85% B for 1 min, to 40% B in 9 min, hold at 40% B for 2 min, then back to 85% B in 0.5 min. The LC system was interfaced with a Sciex QTRAP 6500+ mass spectrometer equipped with a TurboIonSpray (TIS) electrospray ion source. Analyst software (version 1.6.3) was used to control sample acquisition and data analysis. The QTRAP 6500+ mass spectrometer was tuned and calibrated according to the manufacturer's recommendations. Metabolites were detected using MRM transitions that were previously optimized using standards. The instrument was set-up to acquire in negative mode. For quantification, an external standard curve was prepared using a series of standard samples containing different concentrations of metabolites and fixed concentration of the internal standard. The limit of detection for deoxyxylulose 5-phosphate (DOXP), methylerythritol phosphate (MEP), cytidine diphosphate methylerythritol (CDP-ME), and methylerythritol cyclodiphosphate (MEcPP) was 0.0064 μ M for a 10 μ L injection volume. The limit of detection for TCA, Glycolysis and PPP intermediates were as follows: KGLU 0.01 μ M; ACO 0.15 μ M; MAL and SUC 0.2 μ M; FUM and LAC 1 μ M; GLU and PYR 2 μ M; G1P/F6P and G6P 0.5 μ M; GADP 1 μ M; 2PGA/3PGA and PEP 2 μ M; Gly3P 0.25 μ M; Ru5P 1 μ M, S7P 2 μ M.

Metabolite data processing and analysis

Metabolite abundances were log-transformed with pareto scaling to generate normally distributed data. Metabolites with abundances below the limit of detection were imputed at half the value of the lowest measured abundance for that metabolite. Samples were collapsed into two groups, those with parent genotypes and those with mutations in GAPDH. A type III two-way analysis of variance (ANOVA) was performed on each metabolite to test for significant differences across genotype, drug treatment, and/or interaction. A Bonferroni correction was applied to adjust for multiple comparisons. All analysis were performed using the R package of MetaboAnalyst.

Electron microscopy

For ultrastructural analysis, *Plasmodium*-infected red blood cells were fixed in 1% glutaraldehyde (Polysciences Inc., Warrington, PA)/1% osmium tetroxide (Polysciences Inc.) in 50 mM phosphate buffer, pH 7.2 for 1 hr at 4°C. This low osmolarity fixation was used to remove dense, soluble cytoplasmic components, allowing unobscured membrane analysis. Cells were washed in phosphate buffer, rinsed extensively in dH₂O prior to *en bloc* staining with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1 hr. Following several rinses in dH₂O, samples were dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella, Inc.). Sections of 90 nm were cut, stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA, Peabody, MA) at an accelerating voltage of 80kV.

Supporting information

S1 Fig. Fosmidomycin resistance in GAPDH mutant strains from enhancer and cycling screen strains. Representative dose-response curves (from n = 3 experiments), generated using nonlinear regression (GraphPad Prism). Half-maximal inhibitory concentrations (IC₅₀s) for each strain are reported in [S1 Table](#).

(TIFF)

S2 Fig. Relative GAPDH oligomer formation. Absorbance maximums are reported for each of the peaks that correspond to the relative molecular weights for each oligomer. Tetramer, dimer, and monomer, illustrated by number of subunits as shown on the x-axis.

(TIFF)

S3 Fig. Recombinant proteins visualized by SDS-PAGE and Coomassie staining.

(TIFF)

S4 Fig. Michaelis-Menten Kinetics. All curves are representative of experimental triplicates and calculations are derived from the non-linear regression function in GraphPad Prism.

(TIFF)

S5 Fig. FSM disrupts food vacuole integrity. (A) Electron micrograph demonstrating the normal food vacuolar phenotype of *P. falciparum* trophozoites (DMSO treated), characterized by a low electron density vacuole containing dense hemozoin crystals. (B) Electron micrograph illustrating the food vacuole disruption following 12h of FSM treatment (5 μM). Hemozoin crystals are no longer contained by membrane and are now free within the cytosol.

(TIFF)

S6 Fig. Metabolite profiling indicates healthy glycolytic output in *gapdh* mutant strains.

(A) Hierarchical clustering of relative abundances for targeted metabolites are displayed

comparing parent (par) strains versus alternative *gapdh* alleles (mut) in the presence and absence of FSM treatment. Z-scores represent differences within metabolites across samples. (B) Type III two-way ANOVA for targeted metabolites only shows significant differences with respect to drug treatment for 2-C-methyl-D-erythritol-2,4-cyclopyrophosphate (MEcPP) and with respect to genotype for glycerol 3-phosphate (Gly3P). (TIFF)

S7 Fig. *gapdh* mutations do not confer resistance to the IspD inhibitor MMV008138.

MMV008138 inhibits the MEP pathway enzyme IspD competitively with its CTP substrate. Summary EC₅₀ data, determined using GraphPad Prism non-linear regression. (TIFF)

S8 Fig. Exogenous MEP pathway precursors do not rescue FSM inhibition. Exogenous glycolytic metabolites (G3P, glyceraldehyde 3 phosphate; PEP, phosphoenolpyruvate) were supplied at 100 μM. Top, 3D7 wild-type parasite strain. Bottom, *had1* mutant parasite strain. EC₅₀s were calculated using non-linear regression in GraphPad Prism. (TIFF)

S9 Fig. Effect of pH on the activity of purified recombinant GAPDH. The enzymatic activity of purified *P. falciparum* GAPDH was quantified in buffers of increasing pH from 6 to 11, normalized to the maximal activity observed in all conditions. (TIFF)

S1 Table. Whole genome sequencing results.

(CSV)

S1 Data. Raw data underlying size exclusion chromatography, binding data absorbance spectra, heme inhibition, and metabolite profiling.

(XLSX)

Acknowledgments

We thank the Genome Technology Access Center at the McDonnell Genome Institute at Washington University School of Medicine for help with genomic analysis.

Author Contributions

Conceptualization: Andrew J. Jezewski, Ann M. Guggisberg, Audrey Ragan Odom John.

Formal analysis: Andrew J. Jezewski, Ann M. Guggisberg, Audrey Ragan Odom John.

Funding acquisition: Audrey Ragan Odom John.

Investigation: Andrew J. Jezewski, Ann M. Guggisberg, Dana M. Hodge, Naomi Ghebremichael, Gavin Nicholas John, Lisa K. McLellan.

Methodology: Andrew J. Jezewski, Dana M. Hodge, Gavin Nicholas John.

Project administration: Audrey Ragan Odom John.

Supervision: Audrey Ragan Odom John.

Writing – original draft: Andrew J. Jezewski, Audrey Ragan Odom John.

Writing – review & editing: Andrew J. Jezewski, Ann M. Guggisberg, Dana M. Hodge, Naomi Ghebremichael, Lisa K. McLellan, Audrey Ragan Odom John.

References

1. World Malaria Report. 2020.
2. Burrows JN, Burlot E, Campo B, Cherbuin S, Jeanneret S, Leroy D, et al. Antimalarial drug discovery—the path towards eradication. *Parasitology*. 2014; 141: 128–139. <https://doi.org/10.1017/S0031182013000826> PMID: 23863111
3. Matralis AN, Malik A, Penzo M, Moreno I, Almela MJ, Camino I, et al. Development of Chemical Entities Endowed with Potent Fast-Killing Properties against *Plasmodium falciparum* Malaria Parasites. *J Med Chem*. 2019; 62: 9217–9235. <https://doi.org/10.1021/acs.jmedchem.9b01099> PMID: 31566384
4. Klein EY. Antimalarial drug resistance: A review of the biology and strategies to delay emergence and spread. *Int J Antimicrob Agents*. 2013; 41: 311–317. <https://doi.org/10.1016/j.ijantimicag.2012.12.007> PMID: 23394809
5. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. *Nat Rev Microbiol*. 2010; 8: 272–280. <https://doi.org/10.1038/nrmicro2331> PMID: 20208550
6. Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. K13-propeller mutations confer artemisinin resistance in *Plasmodium falciparum* clinical isolates. *Science (80-)*. 2015; 347: 428–431.
7. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperazine resistance in *Plasmodium falciparum* malaria in Cambodia: A multisite prospective cohort study. *Lancet Infect Dis*. 2016; 16: 357–365. [https://doi.org/10.1016/S1473-3099\(15\)00487-9](https://doi.org/10.1016/S1473-3099(15)00487-9) PMID: 26774243
8. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2014; 371: 411–423. <https://doi.org/10.1056/NEJMoa1314981> PMID: 25075834
9. Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking *Plasmodium falciparum* parasite biology to the clinic. *Nat Med*. 2017; 23: 917–928. <https://doi.org/10.1038/nm.4381> PMID: 28777791
10. Rosenthal PJ. Antimalarial drug discovery: old and new approaches. *J Exp Biol*. 2003; 206: 3735–3744. <https://doi.org/10.1242/jeb.00589> PMID: 14506208
11. Sato S. The apicomplexan plastid and its evolution. *Cell Mol Life Sci*. 2011; 68: 1285–1296. <https://doi.org/10.1007/s00018-011-0646-1> PMID: 21380560
12. Kalanon M, McFadden GI. Malaria, *Plasmodium falciparum* and its apicoplast. *Biochem Soc Trans*. 2010; 38: 775–82. <https://doi.org/10.1042/BST0380775> PMID: 20491664
13. Ralph S a, van Dooren GG, Waller RF, Crawford MJ, Fraunholz MJ, Foth BJ, et al. Tropical infectious diseases: metabolic maps and functions of the *Plasmodium falciparum* apicoplast. *Nat Rev Microbiol*. 2004; 2: 203–216. <https://doi.org/10.1038/nrmicro843> PMID: 15083156
14. Zhang B, Watts KM, Hodge D, Kemp LM, Hunstad DA, Hicks LM, et al. A Second Target of the Antimalarial and Antibacterial Agent. 2011; 3570–3577.
15. Odom AR, Van Voorhis WC. Functional genetic analysis of the *Plasmodium falciparum* deoxyxylulose 5-phosphate reductoisomerase gene. *Mol Biochem Parasitol*. 2010; 170: 108–11. <https://doi.org/10.1016/j.molbiopara.2009.12.001> PMID: 20018214
16. Yeh E, DeRisi JL. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage *Plasmodium falciparum*. *PLoS Biol*. 2011; 9: e1001138. <https://doi.org/10.1371/journal.pbio.1001138> PMID: 21912516
17. Guggisberg AM, Amthor RE, Odom AR. Isoprenoid biosynthesis in *Plasmodium falciparum*. *Eukaryot Cell*. 2014; 13: 1348–1359. <https://doi.org/10.1128/EC.00160-14> PMID: 25217461
18. Imlay L, Odom AR. Isoprenoid Metabolism in Apicomplexan Parasites. *Curr Clin Microbiol Reports*. 2014; 1: 37–50. <https://doi.org/10.1007/s40588-014-0006-7> PMID: 25893156
19. Eisenreich W, Bacher A, Arigoni D, Rohdich F. Biosynthesis of isoprenoids via the non-mevalonate pathway. *Cell Mol Life Sci C*. 2004; 61: 1401–1426. <https://doi.org/10.1007/s00018-004-3381-z> PMID: 15197467
20. Ralph SA, D’Ombrain MC, McFadden GI. The apicoplast as an antimalarial drug target. *Drug Resist Updat*. 2001; 4: 145–151. <https://doi.org/10.1054/drup.2001.0205> PMID: 11768328
21. Guggisberg AM, Park J, Edwards RL, Kelly ML, Hodge DM, Tolia NH, et al. A sugar phosphatase regulates the methylerythritol phosphate (MEP) pathway in malaria parasites. *Nat Commun*. 2014; 5: 4467. <https://doi.org/10.1038/ncomms5467> PMID: 25058848
22. Guggisberg AM, Frasse PM, Jezewski AJ, Kafai NM, Gandhi AY, Erlinger SJ, et al. Suppression of drug resistance reveals a genetic mechanism of metabolic plasticity in malaria parasites. *MBio*. 2018; 9: e01193–18. <https://doi.org/10.1128/mBio.01193-18> PMID: 30425143

23. Liberti M V., Dai Z, Wardell SE, Baccile JA, Liu X, Gao X, et al. A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. *Cell Metab.* 2017; 26: 648–659.e8. <https://doi.org/10.1016/j.cmet.2017.08.017> PMID: 28918937
24. Shestov A a, Liu X, Ser Z, Cluntun A a, Hung YP, Huang L, et al. Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. *Elife.* 2014; e03342. <https://doi.org/10.7554/eLife.03342> PMID: 25009227
25. Press P, Ra DOI, Sweeny XEA, Singh AB, Chakravarti XR, Martinez-guzman O, et al. EDITORS ' PICK cro Glyceraldehyde-3-phosphate dehydrogenase is a chaperone that allocates labile heme in cells. 2018; 293: 14557–14568. <https://doi.org/10.1074/jbc.RA118.004169> PMID: 30012884
26. Chakravarti R, Aulak KS, Fox PL, Stuehr DJ. GAPDH regulates cellular heme insertion into inducible nitric oxide synthase. *Proc Natl Acad Sci U S A.* 2010; 107: 18004–18009. <https://doi.org/10.1073/pnas.1008133107> PMID: 20921417
27. Sen N, Hara MR, Kornberg MD, Cascio MB, Bae B-I, Shahani N, et al. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. *Nat Cell Biol.* 2008; 10: 866–873. <https://doi.org/10.1038/ncb1747> PMID: 18552833
28. Tristan C, Shahani N, Sedlak TW, Sawa A. The diverse functions of GAPDH: Views from different sub-cellular compartments. *Cell Signal.* 2011; 23: 317–323. <https://doi.org/10.1016/j.cellsig.2010.08.003> PMID: 20727968
29. Tisdale EJ, Talati NK, Artalejo CR, Shisheva A. GAPDH binds Akt to facilitate cargo transport in the early secretory pathway. *Exp Cell Res.* 2016; 349: 310–319. <https://doi.org/10.1016/j.yexcr.2016.10.025> PMID: 27818247
30. Nicholls C, Li H, Liu J. GAPDH: a common enzyme with uncommon functions. *Clin Exp Pharmacol Physiol.* 2012; 39: 674–679. <https://doi.org/10.1111/j.1440-1681.2011.05599.x> PMID: 21895736
31. Robien M a, Bosch J, Buckner FS, Van Voorhis WC, Worthey E a, Myler P, et al. Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from *Plasmodium falciparum* at 2.25 Å resolution reveals intriguing extra electron density in the active site. *Proteins.* 2006; 62: 570–577. <https://doi.org/10.1002/prot.20801> PMID: 16345073
32. Cook RA, Koshland DE Jr. Positive and negative cooperativity in yeast glyceraldehyde 3-phosphate dehydrogenase. *Biochemistry.* 1970; 9: 3337–3342. <https://doi.org/10.1021/bi00819a007> PMID: 4330855
33. Padmanaban G, Rangarajan PN. Heme metabolism of *Plasmodium* is a major antimalarial target. *Biochem Biophys Res Commun.* 2000; 268: 665–668. <https://doi.org/10.1006/bbrc.1999.1892> PMID: 10679261
34. Sigala P a Goldberg DE. The peculiarities and paradoxes of *Plasmodium* heme metabolism. *Annu Rev Microbiol.* 2014; 68: 259–78. <https://doi.org/10.1146/annurev-micro-091313-103537> PMID: 25002093
35. Howe R, Kelly M, Jimah J, Hodge D, Odom AR. Isoprenoid biosynthesis inhibition disrupts Rab5 localization and food vacuolar integrity in *Plasmodium falciparum*. *Eukaryot Cell.* 2013; 12: 215–23. <https://doi.org/10.1128/EC.00073-12> PMID: 23223036
36. Imlay LS, Armstrong CM, Masters MC, Li T, Price KE, Edwards RL, et al. *Plasmodium* IspD (2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target. *ACS Infect Dis.* 2015; 1: 157. <https://doi.org/10.1021/d500047s> PMID: 26783558
37. Armstrong CM, Meyers DJ, Imlay LS, Meyers CF, Odom AR, Accepted AAC, et al. Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in deoxyxylulose phosphate reductoisomerase (Dxr). *Antimicrob Agents Chemother.* 2015 [cited 2 Jul 2015]. <https://doi.org/10.1128/AAC.00602-15> PMID: 26124156
38. Uh E, Jackson ER, San Jose G, Maddox M, Lee RE, Lee RE, et al. Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. *Bioorg Med Chem Lett.* 2011; 21: 6973–6976. <https://doi.org/10.1016/j.bmcl.2011.09.123> PMID: 22024034
39. Mackie RS, McKenney ES, van Hoek ML. Resistance of *Francisella novicida* to fosmidomycin associated with mutations in the glycerol-3-phosphate transporter. *Front Microbiol.* 2012; 3: 226. <https://doi.org/10.3389/fmicb.2012.00226> PMID: 22905031
40. Sakamoto Y, Furukawa S, Ogihara H, Yamasaki M. Fosmidomycin resistance in adenylate cyclase deficient (cytA) mutants of *Escherichia coli*. *Biosci Biotechnol Biochem.* 2003; 67: 2030–2033. <https://doi.org/10.1271/bbb.67.2030> PMID: 14519998
41. Seeber F, Soldati-Favre D. Metabolic pathways in the apicoplast of apicomplexa. *Int Rev Cell Mol Biol.* 2010; 281: 161–228. [https://doi.org/10.1016/S1937-6448\(10\)81005-6](https://doi.org/10.1016/S1937-6448(10)81005-6) PMID: 20460186
42. Salcedo-Sora JE, Caamano-Gutierrez E, Ward S a., Biagini G a. The proliferating cell hypothesis: a metabolic framework for *Plasmodium* growth and development. *Trends Parasitol.* 2014; 30: 170–175. <https://doi.org/10.1016/j.pt.2014.02.001> PMID: 24636355

43. Hannibal L, Collins D, Brassard J, Chakravarti R, Vempati R, Dorlet P, et al. Heme binding properties of glyceraldehyde-3-phosphate dehydrogenase. *Biochemistry*. 2012; 51: 8514–8529. <https://doi.org/10.1021/bi300863a> PMID: 22957700
44. Pal B. Dissection of heme binding to Plasmodium falciparum glyceraldehyde-3-phosphate dehydrogenase using spectroscopic methods and molecular docking. *Indian J Biochem Biophys*. 2017; 54: 24–31.
45. Sigala P a, Crowley JR, Henderson JP, Goldberg DE. Deconvoluting heme biosynthesis to target blood-stage malaria parasites. *Elife*. 2015; 4: e09143. <https://doi.org/10.7554/eLife.09143> PMID: 26173178
46. Francis SE, Sullivan DJ, Goldberg DE. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. *Annu Rev Microbiol*. 1997; 51: 97–123. <https://doi.org/10.1146/annurev.micro.51.1.97> PMID: 9343345
47. Saliba KJ, Allen RJW, Zissis S, Bray PG, Ward SA, Kirk K. Acidification of the malaria parasite's digestive vacuole by a H⁺-ATPase and a H⁺-pyrophosphatase. *J Biol Chem*. 2003; 278: 5605–5612. <https://doi.org/10.1074/jbc.M208648200> PMID: 12427765
48. Kornberg MD, Sen N, Hara MR, Juluri KR, Nguyen JVK, Snowman AM, et al. GAPDH mediates nitrosylation of nuclear proteins. *Nat Cell Biol*. 2010; 12: 1094–100. <https://doi.org/10.1038/ncb2114> PMID: 20972425
49. Campanale N, Nickel C, Daubenberger C a., Wehlan D a., Gorman JJ, Klonis N, et al. Identification and Characterization of Heme-interacting Proteins in the Malaria Parasite, Plasmodium falciparum. *J Biol Chem*. 2003; 278: 27354–27361. <https://doi.org/10.1074/jbc.M303634200> PMID: 12748176
50. Abshire JR, Rowlands CJ, Ganesan SM, So PTC, Niles JC. Quantification of labile heme in live malaria parasites using a genetically encoded biosensor. *Proc Natl Acad Sci*. 2017; 114: E2068–E2076. <https://doi.org/10.1073/pnas.1615195114> PMID: 28242687
51. Hara MR, Cascio MB, Sawa A. GAPDH as a sensor of NO stress. *Biochim Biophys Acta—Mol Basis Dis*. 2006; 1762: 502–509. <https://doi.org/10.1016/j.bbadis.2006.01.012> PMID: 16574384
52. Daubenberger C a., Tisdale EJ, Curcic M, Diaz D, Silvie O, Mazier D, et al. The N'-Terminal Domain of Glyceraldehyde-3-Phosphate Dehydrogenase of the Apicomplexan Plasmodium falciparum Mediates GTPase Rab2-Dependent Recruitment to Membranes. *Biol Chem*. 2003; 384: 1227–1237. <https://doi.org/10.1515/BC.2003.135> PMID: 12974391
53. Corbett Y, Herrera L, Gonzalez J, Cubilla L, Capson TL, Coley PD, et al. A novel DNA-based micro-fluorimetric method to evaluate antimalarial drug activity. *Am J Trop Med Hyg*. 2004; 70: 119–124. PMID: 14993620